Liver cancer is also known as hepatic cancer. Upon liver cancer diagnosis different treatment methods are adapted like tumor embolization, surgery, targeted therapy, immuno therapy, chemotherapy for treating the disease, extending life span, or relieving symptoms of the patients. Early stage of liver cancer shows no symptoms, usually appears in late stage that leads to increase patients volume available for liver cancer treatment.
Liver Cancer Treatment Market Dynamics
Surge in the prevalence of liver cancer is expected to drive the revenue growth of the market over the forecast period. In accordance with American Cancer Society, in U.S., liver cancer death rates increased by 3% per year since 2000. Liver cancer is the third leading cause of death worldwide and the ninth leading cause of cancer deaths in the US. Liver transplant and surgical resection are curative treatment options for patients in early stage but many patients are not eligible for curative treatments, either due to poor liver function or advanced disease, therefore, the liver cancer medication market is expected to grow in the future. Favorable insurance policies, rise in reimbursements for treatment of liver cancer is expected to fuel the market revenue of liver cancer treatment over the forecast period.
Exposure to environmental chemicals like vinyl chloride, benzene, and lifestyle changes exposing people to the risk of liver cancer. In addition to curative treatments physicians are looking for new treatment options like neoadjuvant and adjuvant therapies to boost the chances of survival rate. Liver Cancer Treatment Market players are focused on developing new drugs which works by targeting specific parts of cancer cells or their surrounding environment. Nexavar and miripla act by hindering new blood vessel and thereby tumor growth, is being studied for use in the early stages of cancer. The pipeline includes the drugs like Thermodox, Imclone Afinitor by Celsion, Eli Lilly and Novartis respectively which shows potential to capture targeted liver cancer drug market. Regorafenib (Stivarga) is a targeted drug, used to treat liver cancers that are no longer responding to sorafenib. Cabozantinib is another targeted drug that has been shown to reduce tumor growth and stop new blood vessel growth in some studies. Chemotherapy drugs, such as oxaliplatin, capecitabine, gemcitabine, and docetaxel, are being tested against liver cancer in clinical trials. Oxaliplatin has shown promising results in early studies when given in combination with doxorubicin and also when given with gemcitabine and the targeted therapy drug cetuximab (Erbitux). In 2017, The U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab), a monoclonal antibody, which is a type of immunotherapy, to treat liver cancer. The drug is marketed by Bristol-Myers Squibb.
Liver Cancer Treatment Market Scope
The Market is segmented based on disease type, therapeutics, and distribution channel.
By Disease Type
- Benign liver growths
- Sorafenib Tosylate (Nexavar)
- Regorafenib (Stivagra)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
Liver Cancer Treatment Market Regional Analysis
The Market has been segmented into North America, Latin America, Europe, Asia-Pacific, and Middle-East & Africa. Important drivers for the market are increasing aging population, drug inventions with respect to the cancer, increasing government initiatives, rising prevalence of cancer and increasing health care expenditure. However, factors such as stringent regulatory processes, high capital investments, and low success rate in clinic trials for drugs and low reach in remote areas are hindering the growth of market. North America is the largest market for liver cancer therapeutics followed by Europe and Asia. Asia-Pacific signifies the fastest growing region for liver cancer therapeutics market, owing to increasing aged populations. Increasing number of liver cancer cases in the Asian countries is anticipated to fuel the market revenue growth. The U.S. Food and Drug Administration (FDA) has expanded the approved use of the targeted therapy drug Stivarga (regorafenib) to treat liver cancer. Sorafenib is proven to add two to three months to the lifespan of a patient with late-stage HCC and a 31% relative reduction in the risk of death.
- Alnylam Pharmaceuticals Inc.
- ImClone Systems Inc.
- Onyx Pharmaceuticals Inc.
- Hoffmann-La Roche Ltd
- Pfizer Inc.
- ArQule Inc.
- Jennerex Biotherapeutics Inc.
- Celsion Corp
- Bristol-Myers Squibb Company
Key Features of the Report:
- The report provides granular level information about the market size, regional market share, historic market (2013-2017) and forecast (2018-2024)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market